SCHEMBL91954

SCHEMBL91954

COc1ccc(C)cc1C(=O)O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A1 P68400 1/20 0.59
ALDH1A1 P00352 8/20 0.56
KDM4E B2RXH2 4/20 0.56
HPGD P15428 3/20 0.56
ACHE P22303 1/20 0.56
LCK P06239 1/20 0.55
FYN P06241 1/20 0.55
MYC P01106 1/20 0.54
CA12 O43570 1/20 0.52
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
CA4 P22748 1/20 0.52
CA6 P23280 1/20 0.52
CA7 P43166 1/20 0.52
TPMT P51580 1/20 0.52
CA9 Q16790 1/20 0.52
CA14 Q9ULX7 1/20 0.52
TDP1 Q9NUW8 2/20 0.52
MAPT P10636 2/20 0.52
HSD17B10 Q99714 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30100430 1.00 CSNK2A1 (0.59) CSNK2A1ALDH1A1KDM4EHPGDACHE
SCHEMBL28837028 0.88 CSNK2A1 (0.59) CSNK2A1ALDH1A1KDM4EHPGDMYC
SCHEMBL365917 0.86 ALDH1A1 (0.65) CSNK2A1ALDH1A1KDM4EHPGDACHE
SCHEMBL9726812 0.85 ACHE (0.58) ALDH1A1HPGDACHEMAPTHSD17B10
SCHEMBL27376288 0.84 CSNK2A1 (0.55) CSNK2A1ALDH1A1KDM4EHPGDMYC
SCHEMBL11003356 0.84 CSNK2A1 (0.55) CSNK2A1ALDH1A1KDM4EHPGDMYC
SCHEMBL29678114 0.84 CSNK2A1 (0.55) CSNK2A1ALDH1A1KDM4EHPGDMYC
SCHEMBL20377181 0.84 CSNK2A1 (0.55) CSNK2A1ALDH1A1KDM4EHPGDMYC
SCHEMBL1210111 0.83 SRC (0.58) ALDH1A1KDM4EACHECA9MAPT
SCHEMBL30482833 0.83 SRC (0.58) ALDH1A1KDM4EACHECA9MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 310 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3112352-A1 OPIOID RECEPTOR MODULATORS Janssen Pharmaceutica NV (BE) 2017-01-04 EP claimed
EP-1725537-B1 NOVEL COMPOUNDS AS OPIOID RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2011-07-13 EP claimed
US-5942365-A CHARGE ADJUVANT OF ALUMINUM SALT OF AN ACID; SMEARING, LOSS OF RESOLUTION AND LOSS OF DENSITY ELIMINATED OR MINIMIZED XEROX CORPORATION (US) 1999-08-24 US claimed
US-12630541-B2 Compounds useful as inhibitors of ALCAT 1 PERENNA PHARMACEUTICALS, INC. (US) 2026-05-19 US disclosed
EP-3782994-B1 COMPOUNDS USEFUL AS KINASE INHIBITORS LOXO ONCOLOGY INC (US) 2025-07-16 EP disclosed
CN-120136858-A Compounds useful as ALCAT1 inhibitors 中美博瑞纳制药有限公司 2025-06-13 CN disclosed
US-20250090500-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS LOXO ONCOLOGY, INC. 2025-03-20 US disclosed
CN-114716381-B Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2025-03-11 CN disclosed
CN-114605327-B Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2025-03-11 CN disclosed
CN-114573510-B Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2025-02-25 CN disclosed
CN-110709394-B Compounds useful as ALCAT1 inhibitors 中美博瑞纳制药有限公司 2025-02-21 CN disclosed
EP-0204472-A2 Cleaning compositions THE PROCTER & GAMBLE COMPANY (US) 1986-12-10 EP disclosed
EP-0187487-A1 Benzothiophenes and benzofurans having antiallergic activity WARNER-LAMBERT COMPANY (US) 1986-07-16 EP disclosed
US-4576728-A AMINE OXIDE, BENZOIC ACID DERIVATIVE HIGH VISCOSITY THE PROCTER & GAMBLE COMPANY (US) 1986-03-18 US disclosed
US-4525304-A Process for preparing oxazolinoazetidinones ELI LILLY AND COMPANY (US) 1985-06-25 US disclosed
EP-0144166-A2 Cleaning compositions THE PROCTER & GAMBLE COMPANY (US) 1985-06-12 EP disclosed
US-4470977-A 3-CHLORO-N-(1-ETHYL-2-PYRROLIDINYLMETHYL2-METHOXYBENZAMIDE ADRIA LABORATORIES, INC. (US) 1984-09-11 US disclosed
EP-0105599-A1 Antiemetic and antipsychotic agents ADRIA LABORATORIES, INC. (US) 1984-04-18 EP disclosed
US-4278680-A Hypoglycaemically and hypolipidaemically active derivatives of phenylacetic acid BOEHRINGER MANNHEIM GMBH (DE) 1981-07-14 US disclosed
US-4207341-A Hypoglycaemically and hypolipidaemically active derivatives of phenylacetic acid BOEHRINGER-MANNHEIM GMBH (DE) 1980-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12630541-B2 Compounds useful as inhibitors of ALCAT 1 LCLAT1, LPCAT1, ACAT2 CSNK2A1 1414/4885ALDH1A1 511/4885KDM4E 3151/4885
US-20250090500-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, ABL1, LCK CSNK2A1 446/4885ALDH1A1 4454/4885KDM4E 619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.